Viewing nowPregabalin Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Huons Co., Ltd.

MFDS item code 201109227 · Approved 2011.10.27 · Insurance code 670605990
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy
This medication is used to relieve peripheral and central neuropathic pain in adults. It is also used as an adjunct for partial seizures in patients with epilepsy and can be useful when there are secondary generalized symptoms. It is effective for the treatment of fibromyalgia, providing relief from pain. Therefore, it is effectively used for various neuropathic pain and seizure-related conditions.
Administer this medicine orally as pregabalin in 2 divided doses per day, with or without food. This medicine is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function (see section 5, “Patients with renal impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section 4, “Discontinuation”). 2. Epilepsy Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, it may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment This medicine is primarily excreted by the kidneys in unchanged form after entering the systemic circulation. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be given after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosing regimen Starting dose (mg/day) Maximum dose (mg/day) TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the dosing regimen. b: Supplemental dose refers to an additional dose given once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts and behaviors, so careful observation for any abnormal changes in mood or behavior during treatment is necessary. Patients with hypersensitivity to this medication or genetic conditions related to lactose should not take it. Diabetes patients may require blood sugar control due to weight gain, and if symptoms of angioedema occur, they should stop taking the medication immediately. Elderly patients should be particularly cautious at the beginning of treatment due to the risk of accidents from dizziness or drowsiness. If you experience blurred vision or changes in eyesight, consult a doctor, as symptoms may improve upon stopping the medication. Caution is advised when switching to this medication as monotherapy, as withdrawal symptoms such as insomnia, headache, and anxiety may occur after discontinuation. Patients with a history of drug abuse should use this medication carefully due to the risk of abuse. Patients with impaired kidney function may require dose adjustments, and those with heart failure should also exercise caution. Care must be taken when taking this medication with opioid analgesics due to the risk of central nervous system depression, and precautions should be taken for patients who may experience respiratory depression. In early pregnancy, there is a risk of fetal malformations, so this medication should not be administered to pregnant women, except in special cases, and women of childbearing age should use effective contraception. Breastfeeding women should consider stopping breastfeeding or discontinuing the medication as it can be transmitted through breast milk. Caution is necessary at the beginning of treatment with this medication due to the risk of accidents from dizziness and drowsiness while driving or operating machinery. Severe skin reactions may occur, so if any unusual skin symptoms appear, the medication should be stopped immediately and a doctor should be consulted. Overdose may result in symptoms such as drowsiness, confusion, and depression, and blood dialysis treatment may be required if necessary. This medication should be kept out of the reach of children and transferring it to another container should be avoided.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to protect it from air and moisture. The recommended storage temperature is at room temperature between 1 to 30 degrees Celsius.
A hard capsule with upper reddish-brown and lower white color containing white or slightly yellow powder.
30 capsules/bottle, 60 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Huons Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.